摘要
美国临床肿瘤学会(ASCO)近年会议发布了大量的阳性和阴性结果,一线治疗的非选择时代已经过去,维持治疗也应该加以选择,二线化疗、靶向治疗各有优势,辅助治疗仍为主导。同时应该重视生物标志物的重要性,生物标志物指导的靶向个体化治疗将大大改善晚期NSCLC患者的预后。
American society of clinical oncology（ASCO） recenfly published amounts of positive and negative clinical trial results of non-small-cell lung cancer（NSCLC）,which poinedt out that the era of first-line therapy to unselected patients has gone with the wind.Maintenance therapy should also be applied to the right patients.Regarding second-line therapy,chemotherapy and targeted therapy both have individual advantages while the adjuvant therapy remained dominant in chemotherapy.Biomarkers-based targeted therapy may dramatically improve the patients＇ survival so the importance of biomarkers should be highlighted.
出处
《临床药物治疗杂志》
2011年第6期16-20,共5页
Clinical Medication Journal
